Sartorius Stedim Biotech S.A. (EPA:DIM)
France · Delayed Price · Currency is EUR 171.20
+1.10 (0.65%)
Jul 31, 2026, 2:43 PM CET
Sartorius Stedim Biotech Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 411 | 373.2 | 219.2 | 401.9 | 1,130 | 646.7 |
Depreciation & Amortization | 160.5 | 318.1 | 301.7 | 236.8 | 181.7 | 141.6 |
Other Adjustments | 165.1 | 175 | 178.8 | 38.1 | -126.9 | 232.7 |
Change in Receivables | 73.6 | 42.9 | 38.3 | 162.1 | -65.8 | -87.3 |
Changes in Inventories | -16.7 | -46.4 | 207.6 | 131.2 | -217.9 | -275.4 |
Changes in Accounts Payable | 33.1 | -21.4 | 2.8 | -87.9 | -68 | 210.3 |
Changes in Income Taxes Payable | -115.2 | -149.1 | -133.5 | -135.8 | -221.2 | -166.6 |
Changes in Other Operating Activities | -80.5 | - | - | - | - | - |
Operating Cash Flow | 788.7 | 692.2 | 815.1 | 746.4 | 612.3 | 701.9 |
Operating Cash Flow Growth | 0.08% | -15.08% | 9.20% | 21.90% | -12.77% | 68.37% |
Capital Expenditures | -394.4 | -393.2 | -339.8 | -473.6 | -430.6 | -324 |
Purchases of Investments | - | -4.4 | -0.1 | -8.1 | - | - |
Cash Acquisitions | - | - | - | -2,241 | -515.6 | -141.7 |
Other Investing Activities | - | - | - | - | -11.4 | 0.4 |
Investing Cash Flow | -397.9 | -397.7 | -340 | -2,723 | -442 | -323.6 |
Long-Term Debt Issued | 295.2 | 13.3 | 17.3 | 2,649 | 566.8 | 74.2 |
Long-Term Debt Repaid | -871.4 | -334.8 | -879.2 | -326.4 | -174.4 | -79.7 |
Net Long-Term Debt Issued (Repaid) | -576.2 | -321.5 | -861.9 | 2,323 | 392.4 | -5.5 |
Issuance of Common Stock | - | 0 | 1,194 | 0 | - | - |
Repurchase of Common Stock | 0.6 | 0.2 | -1.9 | 1.3 | -3.2 | 0 |
Net Common Stock Issued (Repurchased) | 0.6 | 0.2 | 1,192 | 1.3 | -3.2 | 0 |
Common Dividends Paid | -67.1 | -67.1 | -67.1 | -132.7 | -116.1 | -62.7 |
Other Financing Activities | -174.4 | -154.5 | -177.8 | -205.3 | -52.4 | -9.5 |
Financing Cash Flow | -887.7 | -542.8 | 84.9 | 1,986 | 220.7 | -77.7 |
Foreign Exchange Rate Adjustments | 1.5 | -4.5 | 2.3 | -0.3 | 8 | 4.8 |
Net Cash Flow | 94.6 | -248.3 | 560 | 9.8 | -124.5 | 159 |
Free Cash Flow | 394.3 | 299 | 475.3 | 272.8 | 181.7 | 377.9 |
Free Cash Flow Growth | -20.58% | -37.09% | 74.23% | 50.14% | -51.92% | 46.65% |
FCF Margin | 13.12% | 10.08% | 17.10% | 9.83% | 5.20% | 13.09% |
Free Cash Flow Per Share | 4.07 | 3.07 | 4.91 | 2.96 | 1.97 | 4.10 |
Levered Free Cash Flow | -696.8 | -347.9 | -648 | 2,304 | 512.5 | -5.2 |
Unlevered Free Cash Flow | -13.57 | 82.55 | 340.59 | 20.44 | 18.66 | 140.31 |